Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Patients who remained in Study 2
View:
Post by enriquesuave on May 03, 2023 5:06pm

Patients who remained in Study 2

This quote seems to indicate that most probably initial12 not counted after 90 days.  They started off in trial, ( hence included initially then dropped) and since were undertreated are now dropped after 90 days. IMHO 


"The interim clinical data demonstrates a 90 days CR of 54% (n=52) and a sustained duration of response at 450 days of 67% (n=12), for patients who remained in Study II.
Note: To be included in the statistical clinical analysis a patient must be enrolled in Study II, provided the primary Study Treatment
 and evaluated by a Principal Investigator (“PI”) at the 90 day assessment visit (cystoscopy and urine cytology)"
We will eventually get more details, but this must be in line with Statistician they are working with and FDA.  Haven't yet called company.
Comment by N0taP00p on May 03, 2023 5:33pm
I would hope they provide two sets of data one with the 12 included one without. Letter of the law versus spirit of the law,  considering there are bladders at stake. I would also hope they hit the submit button by the time Q1 results are announced in May. 
Comment by Eoganacht on May 03, 2023 5:43pm
The phrase "...patients who remained in Study II" is ambiguous. It could be referring to the exclusion of the first 12 undertreated patients or it could also mean that the patients who developed high grade NMIBC are no longer being evaluated at later time periods. It would certainly be to our advantage if the first is meant and the FDA is allowing the 12 undertreated patients to be ...more  
Comment by wildbird1 on May 03, 2023 6:23pm
Eoganacht..."patients who  remain" could simply refer to the fact that some patients have been removed from study11, as stipulated in the 2Q2020 Newsletter, were TLT said 4/12 undertreated patients were removed from study11.
Comment by enriquesuave on May 03, 2023 7:08pm
Yes Eoganacht.  I would think that even NR patients with progression would be counted as evaluable, and as NR.  It clearly states 8 out of 12 evaluable patients are CR, 2 IR and 2 NR.  With more clarification this will be made clear.
Comment by Eoganacht on May 03, 2023 8:19pm
I very much hope yours is the correct interpretation Enrique. If it is we could be looking at that 50% - 60% complete durable response.
Comment by Eoganacht on May 04, 2023 2:22pm
Just one more senior moment. I meant to write - 40% - 50% complete durable response.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250